TechnoVax: TechnoVax gets NIH grant to develop VLP based respiratory syncytial virus vaccine

US-based biotechnology firm TechnoVax has received a one-year $509,623 SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), to support the development of a vaccine for respiratory syncytial virus (RSV), a major respiratory infectious disease in infants, children and adults.